Drug
Fluoromisonidazole clinical trials
Also written FMISO.
Keep track of what changes. Save the fluoromisonidazole studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 9
Memorial Sloan Kettering Cancer Center (1) · Stanford University (1) · National Cancer Institute (NCI) (1) · Institut Cancerologie de l'Ouest (1) · Siemens Molecular Imaging (1) · OHSU Knight Cancer Institute (1) · University of Alabama at Birmingham (1) · Abramson Cancer Center at Penn Medicine (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses fluoromisonidazole is read from its arms, and is right about nine times in ten.
Testing it · 10
- Feasibility of FMISO in Brain TumorsRecruitingPhase 2OHSU Knight Cancer InstituteNCT03649880Written as ¹⁸F-Fluoromisonidazole
- Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) PatientsCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT02016872Written as 18F-FMISO
- [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver CancerCompletedPhase 2Stanford UniversityNCT02695628Written as 18F-Fluoromisonidazole
- Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) ImagingTerminatedPhase 2University of Alabama at BirminghamNCT03303469Written as FMISO
- Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab TreatmentTerminatedPhase 1Abramson Cancer Center at Penn MedicineNCT03573986Written as [18F]fluoromisonidazole
- MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedPhase 2National Cancer Institute (NCI)NCT00902577Written as FMISO
- FMISO-PET in Brain Tumors and SCS EffectTerminatedPhase 2Bernardino Clavo, MD, PhDNCT01868906Written as 18F-FMISO
- Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate CancerCompletedPhase 2Institut Cancerologie de l'OuestNCT01898065Written as 18-F-MISO
- Clinical Evaluation of the New Hypoxia Imaging Agent HX4CompletedPhase 1/2Siemens Molecular ImagingNCT01213030Written as [F-18] FMISO
- Assessment of Head and Neck Tumor Hypoxia Using 18F-FluoromisonidazoleWithdrawnNot applicableM.D. Anderson Cancer CenterNCT00038038Written as 18F-fluoromisonidazole
Given in every arm · 1 — fluoromisonidazole is usual care beside what is tested
Codes
What other systems call fluoromisonidazole · ClinicalTrials.gg INT002964
- MeSH (NLM) C031843fluoromisonidazoleConfirmed NLM, Wikidata
- UNII (FDA) 082285VIDFFLUOROMISONIDAZOLEConfirmed NLM, Wikidata
- Wikidata Q27236348fluoromisonidazoleConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031843 | fluoromisonidazole | Confirmed NLM, Wikidata |
| UNII (FDA) | 082285VIDF | FLUOROMISONIDAZOLE | Confirmed NLM, Wikidata |
| Wikidata | Q27236348 | fluoromisonidazole | Confirmed NLM, Wikidata |
Also registered as fluoromisonidazole f-18 (UNII 8MSY49469G).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.